Gastrointestinal adverse events after dual Antiplatelet therapy: Clopidogrel is safer than Ticagrelor, but Prasugrel data are lacking or inconclusive

Cardiology (Switzerland)

Volumn 126, Issue 1, 2013, Pages 35-40

  Serebruany, Victor L ^a   Dinicolantonio, James J ^b   Can, Mehmet Mustafa ^c   Pershukov, Igor V ^d   Kuliczkowski, Wiktor ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Wegmans Pharmacy   (United States)

^c Second State University Clinic   (Turkey)

^d Clinical Cardiology   (Russian Federation)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adverse events; Aspirin; Bleeding; Clopidogrel; Dual antiplatelet therapy; Gastrointestinal complications; Hemorrhagic events; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CARCINOMA IN SITU; CARDIAC PATIENT; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; LIVER FUNCTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PERFORATION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOSIS; ULCER; VOMITING; WOUND HEALING IMPAIRMENT; CEREBROVASCULAR ACCIDENT; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEVERE HEPATIC IMPAIRMENT;

ACUTE CORONARY SYNDROME; ADENOSINE; ASPIRIN; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG-INDUCED LIVER INJURY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 84880181722     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000350961     Document Type: Article

References (22)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
2. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
4. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet 2005; 366: 1607-1621.
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
6. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
7. Serebruany VL: Prasugrel and cancer risks: potential causes and implications. Am J Med 2009; 122: 407-408.
8. Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, Abdel-Latif A, Smyth SS: Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013; 35: 147-154.
9. Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner WA, Conte JV, Alejo D, Pastor- Barriuso R, Sharrett AR, Faraday N: Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009; 169: 788-796.
10. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators: A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012; 5: 336-346.
11. Cannon CP, Husted S, Harrington RA, et al: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-STsegment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
12. Leung AM, Redlak MJ, Miller TA: Aspirininduced mucosal cell death in human gastric cells: role of a caspase-independent mechanism. Dig Dis Sci 2009; 54: 28-35.
13. Sostres C, Lanas A: Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011; 8: 385-394.
14. Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K: Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol 2012; 27(suppl 3):8-12.
15. Sostres C, Gargallo CJ: Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2012; 26: 141-151.
16. Sobieraj DM, White CM, Alikhanov S, Winkler S, Mediouni M, Kluger J, Coleman CI: The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: a systematic review. Ann Pharmacother 2012; 46: 1220- 1231.
17. Yeomans ND: Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol 2011; 26: 426-431.
18. Prasugrel Secondary Review. http://www.fda. gov/ohrms/dockets/ac/09/ briefing/2009- 4412b1-00-FDA.htm (accessed October 26, 2012).
19. The FDA ticagrelor review of complete response. http://www.accessdata. fda.gov/drugsa tfda-docs/nda/2011/022433Orig1s000TOC. cfm (accessed October 26, 2012).
20. McMillian WD, Rogers FB: Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. J Trauma 2009; 66: 942-950.
21. Lanas A, Wu P, Medin J, Mills EJ: Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9: 762-768.
22. Roe MT, Armstrong PW, Fox KA, et al: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309.